Afasevikumab

Uses

Afasevikumab (RG 7624; RO 5553110; NI-1401) is a fully human monoclonal IgG1κ antibody neutralizing both IL-17A and IL-17F. Afasevikumab has anti-inflammatory activities[1].

References

[1] Andrea Chiricozzi, et al. Emerging treatment options for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis: evaluating bimekizumab and its therapeutic potential. Psoriasis (Auckl). 2019 May 24;9:29-35. DOI:10.2147/PTT.S179283